IHI is expected to have impacts on the research and innovation ecosystem; on patients and health systems; and on Europe’s competitiveness. Projects funded under the Innovative Medicines Initiative already demonstrate the impacts of the public-private partnership approach to research.

IHI's expected impacts

IHI’s expected long-term impacts are described in the legislation creating IHI:

  • an EU-wide health research and innovation ecosystem that facilitates translation of scientific knowledge into innovations;
  • safe, effective, people-centred and cost effective innovations that respond to strategic unmet public health needs, for example by addressing the prevention, diagnosis, treatment or management of diseases affecting the EU population;
  • a globally competitive European health industry.

In addition, IHI projects will contribute to a number of EU policies, including the new Industrial Strategy for Europe; the Pharmaceutical Strategy for Europe; Europe’s Beating Cancer Plan; the European One Health Action Plan against Antimicrobial Resistance; the SME Strategy for a sustainable and digital Europe and the European Health Data Space. More broadly, IHI should have wider societal and environmental impacts, for example by contributing to the United Nations Sustainable Development Goal 3 on ensuring healthy lives and promoting well-being for all at all ages.

At IHI, we are committed to delivering results that will, in the long term, help to achieve these ambitious impacts. We are therefore preparing a set of IHI-specific key performance indicators (KPIs) that will allow us to monitor our progress.

Once they are finalised, we will report on them in our Annual Activity Reports, which are published online. We will also report on the general KPIs for Horizon Europe and the KPIs that are shared by all joint undertakings (JUs).

IMI's impacts

Meanwhile, the IHI Programme Office continues to monitor and report on the impact of projects launched under the Innovative Medicines Initiative (IMI), IHI's predecessor. The first IMI projects started in 2009, so they have had much longer to deliver results and have an impact.

Examples of IMI impacts include:

  • Over 500 assets (e.g. targets, biomarkers, drug/diagnostic candidates, tools) that have completed a significant milestone during the project.
  • Over 30 regulatory procedures completed, with more on the way. These include letters of support and qualified opinions.
  • Over half of all IMI projects have delivered resources that are available to researchers outside the initial project. These include databases, biobanks, education and training resources, clinical trial networks, guidance documents and tools, and more.
  • IMI projects have also delivered hundreds of tools and processes that are being used by project partners in their day-to-day work.
  • Over 7 000 publications, many of them published in prestigious journals, representing an immense contribution to our knowledge in diverse fields of health research. The Programme Office regularly commissions a bibliometric analysis of these publications; the latest report can be found on this page.

IMI project results and impacts are reported in our annual reports. All IMI Annual Activity Reports (AARs) from 2010 to 2020 can be found on this page. From 2021 on, all IMI project results are reported in the broader IHI Consolidated Annual Activity Reports, which are published on our Plans, Reports and Finances page.